Screener / SEC EDGAR /CIK 0001802768 /10-K filed Feb 11, 2026, compared with Feb 12, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Royalty Pharma plc RPRX

Compare with peers Embed
Planned sales, announced before they happen

5 trading plans running, 37 Form 144 notices for $144.3M

10-Q, 10-K and Form 144
Plans running now 5 Chris Hite, Marshall Urist, M.D., Ph.D., Terrance Coyne, Christopher Hite, Gregory Norden
Plans adopted 15 reported since May 9, 2023 Form 144 notices 37 $144.3M the sellers expected to sell

What RPRX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Aug 20, 2025 to Mar 12, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Chris Hite
Executive Vice President & Chairman, Partnering & Investments
Adopted 10b5-1 plan Sep 21, 2026 10-Q Nov 4, 2026
Marshall Urist, M.D., Ph.D.
Executive Vice President, Research & Investments
Adopted 10b5-1 plan Aug 7, 2026 10-Q Nov 4, 2026
Terrance Coyne
Executive Vice President & Chief Financial Officer
Adopted 10b5-1 plan Aug 6, 2026 10-Q Nov 4, 2026
Marshall Urist, M.D., Ph.D.
Executive Vice President, Research & Investments
Adopted 10b5-1 plan Jun 26, 2026 10-Q Aug 5, 2026
What the company wrote
The following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the second quarter of 2026, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”): Name and Title Action Adoption/ Termination Date Scheduled Expiration Date of Trading Plan (1) Maximum Shares Subject to Trading Plan Marshall Urist, M.D., Ph.D. Executive Vice President, Research & Investments Adoption June 26, 2026 October 9, 2026 EPA Shares (2) (1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan. (2) On June 26, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on September 28, 2026 and end on October 9, 2026, providing for the sale of up to 100% of the Class A ordinary shares that may be issued upon settlement of EPAs in August 2026.
Christopher Hite
Executive Vice President & Chairman, Partnering & Investments
Adopted 10b5-1 plan Mar 20, 2026 10-Q May 6, 2026
Terrance Coyne
Executive Vice President & Chief Financial Officer
Adopted 10b5-1 plan Feb 24, 2026 10-Q May 6, 2026
Gregory Norden
Director
Adopted 10b5-1 plan Feb 12, 2026 10-Q May 6, 2026
Marshall Urist, M.D., Ph.D.
Executive Vice President, Research & Investments
Adopted 10b5-1 plan Feb 12, 2026 10-Q May 6, 2026
Marshall Urist, M.D., Ph.D.
Executive Vice President, Research & Investments
Adopted 10b5-1 plan Sep 16, 2025 10-Q Nov 5, 2025
George Lloyd
Executive Vice President, Investments & Chief Legal Officer
Adopted 10b5-1 plan Aug 20, 2025 10-Q Nov 5, 2025
Terrance Coyne
Executive Vice President & Chief Financial Officer
Adopted 10b5-1 plan Aug 8, 2025 10-Q Nov 5, 2025
Marshall Urist
Executive Vice President, Research and Investments
Ended 10b5-1 plan Mar 21, 2024 10-Q May 9, 2024
Terrance Coyne
Executive Vice President & Chief Financial Officer
Ended 10b5-1 plan Mar 6, 2024 10-Q May 9, 2024
Marshall Urist
Executive Vice President, Research and Investments
Adopted 10b5-1 plan Dec 20, 2023 10-K Feb 15, 2024
Terrance Coyne
Executive Vice President & Chief Financial Officer
Adopted 10b5-1 plan Nov 22, 2023 10-K Feb 15, 2024
Marshall Urist
Executive Vice President, Research and Investments
Adopted 10b5-1 plan Sep 29, 2023 10-Q Nov 8, 2023
Rory Riggs
Director
Adopted 10b5-1 plan Sep 29, 2023 10-Q Nov 8, 2023
Terrance Coyne
Executive Vice President & Chief Financial Officer
Ended 10b5-1 plan Sep 12, 2023 10-Q Nov 8, 2023
Show the other 10 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Oct 5, 2026 Urist Marshall
Officer
4,126 $236K
Sep 28, 2026 Urist Marshall
Officer
4,126 $239K
Sep 22, 2026 SCH Investment Partners LLC
Officer
100,000 $5.8M
Aug 18, 2026 SCH Investment Partners LLC
Officer
100,000 $6.0M
Aug 13, 2026 Terrance Coyne
Officer
11,002 $644K
Aug 12, 2026 Errol B. De Souza
Former Affiliate
206,352 $11.9M
Aug 12, 2026 Errol B. De Souza
Former Affiliate
125,000 $7.2M
Jul 1, 2026 Urist Marshall
Officer
9,099 $508K
Jul 1, 2026 SCH Investment Partners LLC
Officer
100,000 $5.7M
Jun 24, 2026 Urist Marshall
Officer
9,098 $502K
Jun 23, 2026 Christopher Hite
Officer
30,000 $1.7M
Jun 23, 2026 SCH Investment Partners LLC
Officer
150,000 $8.2M
May 26, 2026 Terrance Coyne
Officer
64,399 $3.5M
May 20, 2026 Urist Marshall
Officer
13,684 $722K
May 14, 2026 Norden Gregory
Officer
3,045 $161K
May 14, 2026 Urist Marshall
Officer
13,684 $726K
Apr 28, 2026 Terrance Coyne
Officer
34,791 $1.7M
Apr 1, 2026 Terrance Coyne
Officer
34,791 $1.7M
Mar 23, 2026 Terrance Coyne
Officer
34,791 $1.6M
Mar 19, 2026 George Lloyd
Officer
36,518 $1.7M
Mar 18, 2026 George Lloyd
Officer
100,462 $4.6M
Mar 4, 2026 George Lloyd
Officer
136,980 $6.5M
Mar 2, 2026 Terrance Coyne
Officer
34,791 $1.7M
Feb 23, 2026 Terrance Coyne
Officer
34,791 $1.6M
Feb 3, 2026 Terrance Coyne
Officer
135,117 $5.8M
Feb 2, 2026 Terrance Coyne
Officer
108,424 $4.6M
Jan 20, 2026 Terrance Coyne
Officer
69,582 $2.7M
Jan 7, 2026 George Lloyd
Officer
495,860 $20.5M
Jan 2, 2026 Terrance Coyne
Officer
69,582 $2.7M
Dec 16, 2025 Sandy Lamm LLC
Officer
160,000 $6.1M
Dec 15, 2025 Terrance Coyne
Officer
69,582 $2.7M
Dec 1, 2025 Urist Marshall
Officer
36,484 $1.5M
Dec 1, 2025 Terrance Coyne
Officer
69,582 $2.8M
Dec 1, 2025 Sandy Lamm LLC
Officer
46,667 $930K
Nov 24, 2025 Terrance Coyne
Officer
69,582 $2.8M
Nov 19, 2025 George Lloyd
Officer
355,426 $13.7M
Nov 17, 2025 Terrance Coyne
Officer
69,594 $2.7M
Show the other 29 notices

From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RPRX/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.